Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (ARWR:NSQ) closed at 21.89, 28.39% above the 52 week low of 17.05 set on Oct 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.35 |
---|---|
High | 21.92 |
Low | 21.00 |
Bid | 21.40 |
Offer | 21.93 |
Previous close | 21.39 |
Average volume | 1.01m |
---|---|
Shares outstanding | 124.32m |
Free float | 118.76m |
P/E (TTM) | -- |
Market cap | 2.72bn USD |
EPS (TTM) | -4.65 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
- Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
- Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
- Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
- Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
More ▼